Diagnosis of pre-eclampsia
AssigneeKing's College London
InventorsLucilla Poston, Paul Townsend Seed, Beverley Jane Hunt, Lucy Charlotte Chappell
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (PIGF), plasminogen activator inhibitor-1 (PAI-1) plasminogen activator inhibitor-2 (PAI-2) and leptin.
Claims19
A method of predicting whether a pregnant human will subsequently develop pre-eclampsia (PE), comprising:
- determining in a blood sample of the pregnant human a level of placenta growth factor (P1GF) protein and a level of at least one protein or protein ratio selected from the group consisting of:
- i) ratio of plasminogen activator inhibitor-1 (PAI-1) to plasminogen activator inhibitor-2 (PAI-2);
- and
- ii) leptin;
- and
- providing a prediction as to whether the pregnant human will subsequently develop PE based on a) the level of P1GF protein and the ratio of PAI-1 protein to PAI-2 protein, or b) the level of P1GF protein and the level of leptin protein.
A method of predicting whether a pregnant human will subsequently develop pre-eclampsia (PE), comprising:
- determining in a blood sample of the pregnant human a level of placenta growth factor (P1GF) protein and a level of plasminogen activator inhibitor-2 (PAI-2) protein, wherein a prediction that the pregnant human will subsequently develop PE is given when combined levels of proteins P1GF and PAI-2 in the sample are less than combined levels found in normal pregnant humans, wherein the levels of proteins P1GF and PAI-2 are combined to form the combined levels using the algorithm:
- d(loge[PAI-2])+(loge[PlGF])
- wherein d is a constant in the range of about 0.03 to 48.6;
- and
- providing a prediction as to whether the pregnant human will subsequently develop PE based on the determined combined levels.
A method of predicting whether a pregnant human will subsequently develop pre-eclampsia (PE), comprising:
- determining in a blood sample of the pregnant human a level of placenta growth factor (P1GF) protein and a level of plasminogen activator inhibitor-2 (PAI-2) protein, wherein a prediction that the pregnant human will subsequently develop PE is given when combined levels of proteins P1GF and PAI-2 in the sample are less than combined levels found in normal pregnant humans, and wherein the level of proteins P1GF and PAI-2 are combined to form the combined levels using the algorithm:
- [PAI-2]d*[PlGF]
- wherein d is a constant in the range of about 0.03 to 48.6;
- and
- providing a prediction as to whether the pregnant human will subsequently develop PE based on the determined combined levels.
A method of predicting whether a pregnant human will subsequently develop pre-eclampsia (PE), comprising:
- determining in a blood sample of the pregnant human a level of placenta growth factor (P1GF) protein and a level of plasminogen activator inhibitor-2 (PAI-2) protein, wherein a prediction that the pregnant human will subsequently develop PE is given when combined levels of proteins P1GF and PAI-2 in the sample are less than combined levels found in normal pregnant humans, and wherein the level of proteins P1GF and PAI-2 are combined to form the combined level using the algorithm:
- [PAI-2]*[PlGF];
- and
- providing a prediction as to whether the pregnant human will subsequently develop PE based on the determined combined levels.
A method of predicting whether a pregnant human will subsequently develop pre-eclampsia (PE), comprising:
- determining in a blood sample of the pregnant human a level of placenta growth factor (P1GF) protein and a level of one protein ratio selected from the group consisting of:
- (i) the ratio of plasminogen activator inhibitor-1 (PAI-1) to plasminogen activator inhibitor-2 (PAI-2);
- and
- (ii) the ratio of leptin/P1GF;
- and providing a prediction as to whether the pregnant human will subsequently develop PE based on a) the level of P1GF protein and the PAI-1/PAI-2 protein ratio, or b) the level of P1GF protein and the leptin/P1GF protein ratio.
A method of predicting whether a pregnant human will subsequently develop pre-eclampsia (PE), comprising:
- determining in a blood sample of the pregnant human a level of placenta growth factor (P1GF) protein and a level of plasminogen activator inhibitor-2 (PAI-2) protein, wherein a prediction that the pregnant human will subsequently develop PE is given when combined levels of proteins P1GF and PAI-2 in the sample are less than combined levels found in normal pregnant humans, and wherein the level of proteins P1GF and PAI-2 are combined to form the combined level using the algorithm:
- 0.75 (logePAI-2)+(logeP1GF);
- and
- providing a prediction as to whether the pregnant human will subsequently develop PE based on the determined combined levels.
Dependencies are inferred from the claim text.